A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

por Fleseriu, M., Zhang, Z., Hanman, K., Haria, K., Houchard, A., Khawaja, S., Ribeiro-Oliveira, A., Gadelha, M.
Publicado 2022

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

por Boscaro, M., Bertherat, J., Findling, J., Fleseriu, M., Atkinson, A. B., Petersenn, S., Schopohl, J., Snyder, P., Hughes, G., Trovato, A., Hu, K., Maldonado, M., Biller, B. M. K.
Publicado 2013

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results

por Labadzhyan, Artak, Nachtigall, L B, Fleseriu, M, Gordon, M B, Molitch, M, Kennedy, L, Samson, S L, Greenman, Y, Biermasz, N, Bolanowski, M, Haviv, A, Ludlam, W, Patou, G, Strasburger, C J
Publicado 2021

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results

por Labadzhyan, Artak, Nachtigall, L B, Fleseriu, M, Gordon, M B, Molitch, M, Kennedy, L, Samson, S L, Greenman, Y, Biermasz, N, Bolanowski, M, Haviv, A, Ludlam, W, Patou, G, Strasburger, C J
Publicado 2021

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

por Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., Fleseriu, M., van der Lely, A. J., Farrall, A. J., Hermosillo Reséndiz, K., Ruffin, M., Chen, Y., Sheppard, M.
Publicado 2014